Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PPOX | P50336 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839852 | 0.79 | ITGAL (0.44) | — | |
| SCHEMBL5203833 | 0.79 | ITGB2 (0.50) | P2RX3MAPK1ALDH1A1PTGS2PTGS1 | |
| SCHEMBL4845339 | 0.78 | P2RX3 (0.36) | P2RX3LMNAMAPK1HTTMAPT | |
| SCHEMBL4848463 | 0.76 | HSD11B1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL4847341 | 0.74 | LTA4H (0.36) | GRM4LMNAALDH1A1MAPT | |
| SCHEMBL4847608 | 0.73 | ITGAL (0.41) | — | |
| SCHEMBL4841565 | 0.73 | ITGAL (0.41) | — | |
| SCHEMBL16349444 | 0.73 | ITGAL (0.35) | LMNAALDH1A1HTTTSHR | |
| SCHEMBL4841707 | 0.69 | ITGAL (0.55) | — | |
| SCHEMBL4846983 | 0.69 | ITGAL (0.42) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1307455-B1 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| EP-1307455-A2 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-07 | — | — | EP | disclosed |
| WO-2001030781-A2 | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | P2RX3 2196/4885GRM4 4126/4885LMNA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.